Table 4. Correlations between ΔSUVmax and clinical variables.
| No. of patients | DSUVmax median of the treated lesions (standard deviation) | P | |
|---|---|---|---|
| Local control (months)A | |||
| <6 | 10 | 42 (28) | |
| 6-12 | 12 | 62 (18) | |
| >12 | 25 | 78 (23) | <0.001 |
| Chemotherapy before SRT | |||
| No | 29 | 64 (16) | |
| Yes | 18 | 68 (22) | 0.293 |
| Response to first-line chemotherapy | |||
| RC, RP, SD | 37 | 69 (26) | |
| PD | 6 | 62 (19) | 0.348 |
| Anti-VEGF therapy before SRT | |||
| Yes | 11 | 73 (15) | |
| No | 5 | 56 (20) | 0.0512 |
| Overall survival | |||
| ≤2 years | 9 | 46 (17) | |
| >2 years | 38 | 75 (22) | 0.003 |
| Sites of disease | |||
| Lung | 21 | 67 (16) | |
| Liver | 7 | 58 (28) | |
| Lung and liver | 9 | 71 (15) | |
| Presence of LN metastases | 10 | 77 (20) | 0.091 |
| KRAS mutational status | |||
| Wilde Type | 29 | 69 (14) | |
| Mutated | 18 | 61 (19) | 0.462 |
A: from the date of the first SRT application to the evidence of progression of the irradiate site.